PL2578688T3 - Myszy adam6 - Google Patents

Myszy adam6

Info

Publication number
PL2578688T3
PL2578688T3 PL12192727T PL12192727T PL2578688T3 PL 2578688 T3 PL2578688 T3 PL 2578688T3 PL 12192727 T PL12192727 T PL 12192727T PL 12192727 T PL12192727 T PL 12192727T PL 2578688 T3 PL2578688 T3 PL 2578688T3
Authority
PL
Poland
Prior art keywords
adam6 mice
adam6
mice
Prior art date
Application number
PL12192727T
Other languages
English (en)
Other versions
PL2578688T5 (pl
Inventor
Lynn Macdonald
Sean Stevens
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2578688(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL2578688T3 publication Critical patent/PL2578688T3/pl
Publication of PL2578688T5 publication Critical patent/PL2578688T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL12192727.1T 2011-02-25 2012-02-24 Myszy adam6 PL2578688T5 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
EP12716101.6A EP2550363B1 (en) 2011-02-25 2012-02-24 Adam6 mice
PCT/US2012/026416 WO2012141798A1 (en) 2011-02-25 2012-02-24 Adam6 mice
EP12192727.1A EP2578688B2 (en) 2011-02-25 2012-02-24 ADAM6 mice

Publications (2)

Publication Number Publication Date
PL2578688T3 true PL2578688T3 (pl) 2020-05-18
PL2578688T5 PL2578688T5 (pl) 2023-05-29

Family

ID=45998616

Family Applications (5)

Application Number Title Priority Date Filing Date
PL14154918.8T PL2738258T5 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL12716101T PL2550363T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL22156414.9T PL4067496T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL12192727.1T PL2578688T5 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL14154967T PL2738259T3 (pl) 2011-02-25 2012-02-24 Myszy adam6

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL14154918.8T PL2738258T5 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL12716101T PL2550363T3 (pl) 2011-02-25 2012-02-24 Myszy adam6
PL22156414.9T PL4067496T3 (pl) 2011-02-25 2012-02-24 Myszy adam6

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14154967T PL2738259T3 (pl) 2011-02-25 2012-02-24 Myszy adam6

Country Status (32)

Country Link
US (12) US8642835B2 (pl)
EP (7) EP4067496B1 (pl)
JP (7) JP2014507137A (pl)
KR (1) KR101387377B1 (pl)
CN (2) CN105861548B (pl)
AU (5) AU2012243291B2 (pl)
BR (1) BR112013021771B1 (pl)
CA (1) CA2820824A1 (pl)
CY (5) CY1116301T1 (pl)
DE (5) DE14154918T1 (pl)
DK (6) DK2738258T4 (pl)
ES (6) ES2805364T3 (pl)
FI (3) FI2578688T4 (pl)
HK (2) HK1174490A1 (pl)
HR (5) HRP20191895T4 (pl)
HU (5) HUE046746T2 (pl)
IL (4) IL226727A (pl)
IN (1) IN2013CN07629A (pl)
LT (4) LT4067496T (pl)
ME (3) ME02106B (pl)
MX (2) MX343009B (pl)
MY (1) MY172713A (pl)
NZ (2) NZ731926A (pl)
PL (5) PL2738258T5 (pl)
PT (5) PT2550363E (pl)
RS (5) RS64280B1 (pl)
RU (2) RU2722373C2 (pl)
SG (4) SG10201405135RA (pl)
SI (5) SI2578688T2 (pl)
SM (1) SMT201500061B (pl)
WO (1) WO2012141798A1 (pl)
ZA (1) ZA201305998B (pl)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
LT2311874T (lt) 2004-07-22 2017-11-27 Erasmus University Medical Center Rotterdam Rišančiosios molekulės
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
PT2421357E (pt) * 2009-07-08 2013-04-18 Kymab Ltd Modelos animais e moléculas terapêuticas
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ME02288B (me) 2010-02-08 2016-02-20 Regeneron Pharma Miš sa zajedničkim lakim lancem
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
RS64280B1 (sr) 2011-02-25 2023-07-31 Regeneron Pharma Adam6 miševi
WO2013006688A2 (en) 2011-07-05 2013-01-10 Duke University N-terminal deleted gp120 immunogens
IL273982B2 (en) * 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP3128009B1 (en) 2011-09-19 2020-07-29 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
WO2013052095A2 (en) 2011-10-03 2013-04-11 Duke University Vaccine
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013096142A1 (en) * 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
SG10201606256TA (en) * 2012-02-01 2016-09-29 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
NZ629639A (en) 2012-03-16 2017-03-31 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
KR102345232B1 (ko) 2012-03-16 2021-12-30 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
MX2014011047A (es) 2012-03-16 2015-04-08 Regeneron Pharma Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
NZ630568A (en) 2012-04-20 2017-06-30 Merus Nv Methods and means for the production of ch3 domain-comprising molecules
US10238093B2 (en) * 2012-06-12 2019-03-26 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
US9963501B2 (en) 2013-02-06 2018-05-08 Regeneron Pharmaceuticals, Inc. B cell lineage based immunogen design with humanized animals
EP3351095A1 (en) 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
ES2829376T3 (es) * 2013-03-14 2021-05-31 Univ Erasmus Med Ct Rotterdam Mamífero no humano transgénico para la producción de anticuerpos
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
KR20230158661A (ko) * 2014-03-21 2023-11-21 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
BR112017005245A2 (pt) 2014-09-19 2017-12-12 Regeneron Pharma animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
RU2763320C2 (ru) 2016-01-13 2021-12-28 Регенерон Фармасьютикалз, Инк. Грызуны, имеющие сконструированный участок разнообразия тяжелой цепи
JP2019509059A (ja) 2016-02-16 2019-04-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異型キヌレニナーゼ遺伝子を有する非ヒト動物
BR112018073750A2 (pt) * 2016-05-20 2019-02-26 Regeneron Pharmaceuticals, Inc. métodos para gerar proteínas de ligação ao antígeno contra um antígeno estranho de interesse e para produzir um animal não humano geneticamente modificado com tolerância reduzida de um antígeno estranho de interesse
AU2017272337C1 (en) 2016-06-03 2024-02-29 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
AU2017391167B2 (en) 2016-11-04 2024-02-15 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US20210345591A1 (en) 2017-12-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
EP3772927A1 (en) 2018-03-24 2021-02-17 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
KR20210004994A (ko) 2018-03-26 2021-01-13 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
US20210079109A1 (en) 2018-05-17 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL279311B2 (en) 2018-06-14 2024-02-01 Regeneron Pharma Non-human animals capable of DH–DH rearrangements in immunoglobulin heavy chain coding sequences
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH A HUMANIZED IMMUNOGLOBULIN LOCUS
CA3127153A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
MX2021014893A (es) 2019-06-05 2022-03-11 Regeneron Pharma Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
EP3785536B1 (en) * 2019-08-28 2022-01-26 Trianni, Inc. Adam6 knockin mice
US20220409732A1 (en) 2019-12-02 2022-12-29 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
AU2021283564A1 (en) 2020-06-02 2022-12-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
BR112023011689A2 (pt) 2020-12-23 2023-10-31 Regeneron Pharma Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero
US20220195014A1 (en) 2020-12-23 2022-06-23 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
WO2022225985A1 (en) 2021-04-20 2022-10-27 Regeneron Pharmaceuticals, Inc. Human antibodies to artemin and methods of use thereof
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08503617A (ja) * 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Ｌ−セレクチンに反応性のヒト化抗体
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
JP2003501016A (ja) * 1999-05-27 2003-01-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ａｄａｍのポリヌクレオチドおよびポリペプチド
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
CN1789416B (zh) * 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
EP2767161B1 (en) 2004-10-19 2018-02-07 Regeneron Pharmaceuticals, Inc. Method for generating an non-human animal homozygous for a genetic modification
EP1739691B1 (en) 2005-06-30 2008-12-03 Borealis Technology Oy Outer sheath layer for power or communication cable
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
ES2908040T3 (es) 2008-09-30 2022-04-27 Ablexis Llc Ratones con inserción génica para la producción de anticuerpos quiméricos
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
PT2421357E (pt) * 2009-07-08 2013-04-18 Kymab Ltd Modelos animais e moléculas terapêuticas
PL2509409T3 (pl) * 2009-12-10 2017-02-28 Regeneron Pharmaceuticals, Inc. Myszy wytwarzające przeciwciała ciężkołańcuchowe
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ME02288B (me) 2010-02-08 2016-02-20 Regeneron Pharma Miš sa zajedničkim lakim lancem
EP2582230A1 (en) * 2010-06-17 2013-04-24 Kymab Limited Animal models and therapeutic molecules
RS64280B1 (sr) 2011-02-25 2023-07-31 Regeneron Pharma Adam6 miševi
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013096142A1 (en) 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice

Also Published As

Publication number Publication date
CN103429746A (zh) 2013-12-04
JP2018143250A (ja) 2018-09-20
RS64280B1 (sr) 2023-07-31
IL273986A (en) 2020-05-31
EP3744850A1 (en) 2020-12-02
ES2748832T5 (es) 2023-06-08
US10694725B2 (en) 2020-06-30
EP2738259A2 (en) 2014-06-04
FI2578688T4 (fi) 2023-05-05
EP2550363B1 (en) 2014-12-10
ES2805364T3 (es) 2021-02-11
RS59413B1 (sr) 2019-11-29
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
US20150201589A1 (en) 2015-07-23
SI2738258T1 (sl) 2020-01-31
PL2550363T3 (pl) 2015-05-29
US8697940B2 (en) 2014-04-15
AU2015238806A1 (en) 2015-10-29
CY1122820T1 (el) 2021-05-05
NZ612643A (en) 2015-06-26
ES2770424T3 (es) 2020-07-01
AU2012243291B2 (en) 2015-07-09
AU2017251802A1 (en) 2017-11-16
SI4067496T1 (sl) 2023-07-31
DK2813573T1 (da) 2015-01-12
US10577430B2 (en) 2020-03-03
RS59929B1 (sr) 2020-03-31
HRP20191895T1 (hr) 2020-01-10
US10905109B2 (en) 2021-02-02
JP2014507137A (ja) 2014-03-27
HRP20230526T1 (hr) 2023-09-01
US10072095B2 (en) 2018-09-11
IL273986B (en) 2021-04-29
NZ776770A (en) 2023-03-31
RS53880B1 (en) 2015-08-31
ES2946169T3 (es) 2023-07-13
US20180346598A1 (en) 2018-12-06
EP4067496A1 (en) 2022-10-05
RU2582261C2 (ru) 2016-04-20
JP2019187446A (ja) 2019-10-31
CN105861548A (zh) 2016-08-17
DE14176593T1 (de) 2015-03-05
HUE046081T2 (hu) 2020-01-28
ES2758974T3 (es) 2020-05-07
DK2578688T3 (da) 2019-10-28
PL4067496T3 (pl) 2023-07-31
IL226727A (en) 2016-08-31
BR112013021771A2 (pt) 2017-07-04
EP2813573A1 (en) 2014-12-17
PL2578688T5 (pl) 2023-05-29
JP2015107131A (ja) 2015-06-11
CN103429746B (zh) 2016-05-11
EP2578688A1 (en) 2013-04-10
DE12192727T1 (de) 2013-07-11
US20130254911A1 (en) 2013-09-26
SI2578688T2 (sl) 2023-05-31
NZ703609A (en) 2016-04-29
EP2738258A2 (en) 2014-06-04
PL2738258T3 (pl) 2020-08-24
IL261243B (en) 2019-08-29
DK4067496T3 (da) 2023-06-26
KR20130116375A (ko) 2013-10-23
ZA201305998B (en) 2016-07-27
US20210105985A1 (en) 2021-04-15
LT2578688T (lt) 2019-11-11
CY1122459T1 (el) 2021-01-27
RU2013125717A (ru) 2014-12-10
IL261243A (en) 2018-10-31
DE14154918T1 (de) 2014-08-21
SG10201405135RA (en) 2014-10-30
MX343009B (es) 2016-10-21
US20240306617A1 (en) 2024-09-19
PT2738259T (pt) 2020-02-18
US20140213773A1 (en) 2014-07-31
JP2014110814A (ja) 2014-06-19
EP2813573B1 (en) 2020-04-22
HUE047687T2 (hu) 2020-05-28
KR101387377B1 (ko) 2014-04-21
EP2578688B1 (en) 2019-07-24
MX2013009649A (es) 2013-09-26
HRP20192311T1 (hr) 2020-03-20
DK2550363T3 (en) 2015-03-23
US9944716B2 (en) 2018-04-17
AU2020201279A1 (en) 2020-03-12
FI2738258T4 (fi) 2023-05-05
DE12716101T1 (de) 2013-05-08
PL2738259T3 (pl) 2020-08-24
US20150210776A1 (en) 2015-07-30
SI2738258T2 (sl) 2023-05-31
DK2738258T3 (da) 2019-12-16
NZ718688A (en) 2017-07-28
IN2013CN07629A (pl) 2015-08-07
CY1116301T1 (el) 2017-02-08
CN105861548B (zh) 2020-01-10
LT2738258T (lt) 2020-01-10
RU2016109443A (ru) 2018-11-26
LT2738259T (lt) 2020-03-10
SMT201500061B (it) 2015-05-05
HUE062552T2 (hu) 2023-11-28
EP2578688B2 (en) 2023-02-08
MX2020009714A (es) 2020-10-07
DK2738258T1 (da) 2014-11-24
DK2738258T4 (da) 2023-05-08
WO2012141798A1 (en) 2012-10-18
PT2738258T (pt) 2019-12-10
US20180346599A1 (en) 2018-12-06
HUE046746T2 (hu) 2020-03-30
ME03537B (pl) 2020-04-20
MY172713A (en) 2019-12-11
US20120322108A1 (en) 2012-12-20
RU2722373C2 (ru) 2020-05-29
HK1201292A1 (en) 2015-08-28
EP2738258B1 (en) 2019-09-25
EP2738258A3 (en) 2014-09-24
ES2532487T3 (es) 2015-03-27
SG10201913155QA (en) 2020-02-27
EP2550363A1 (en) 2013-01-30
PT2550363E (pt) 2015-03-16
CY1122205T1 (el) 2020-11-25
ES2748832T3 (es) 2020-03-18
CY1126091T1 (el) 2023-11-15
DE14154967T1 (de) 2014-08-28
DK2738259T1 (da) 2014-11-24
EP4067496B1 (en) 2023-03-29
EP2738258B2 (en) 2023-02-01
AU2012243291A1 (en) 2013-05-09
HUE024534T2 (hu) 2016-01-28
HRP20191895T4 (hr) 2023-05-12
SI2578688T1 (sl) 2019-11-29
JP5866127B2 (ja) 2016-02-17
US9932408B2 (en) 2018-04-03
JP2016135143A (ja) 2016-07-28
SG10201913160QA (en) 2020-03-30
HRP20150262T1 (hr) 2015-04-10
NZ731926A (en) 2021-07-30
DK4067496T5 (da) 2024-07-22
BR112013021771B1 (pt) 2022-11-16
SG192933A1 (en) 2013-09-30
CA2820824A1 (en) 2012-10-18
JP2022071051A (ja) 2022-05-13
HRP20192311T4 (hr) 2023-05-12
EP2738259A3 (en) 2014-07-30
ES2758974T5 (es) 2023-06-08
RS59413B2 (sr) 2023-06-30
US10905108B2 (en) 2021-02-02
HK1174490A1 (en) 2013-06-14
FI4067496T3 (fi) 2023-05-24
US8642835B2 (en) 2014-02-04
LT4067496T (lt) 2023-06-12
ME02106B (me) 2015-10-20
EP2738259B1 (en) 2019-11-27
DK2578688T4 (da) 2023-05-08
RU2016109443A3 (pl) 2019-07-24
ME03732B (me) 2021-01-20
PT4067496T (pt) 2023-06-07
IL268671A (en) 2019-10-31
IL268671B (en) 2020-05-31
DK2578688T1 (da) 2014-11-24
RS59661B2 (sr) 2023-06-30
HRP20200294T1 (hr) 2020-05-29
DK2738259T3 (da) 2020-02-17
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
AU2022206806A1 (en) 2022-08-18
US20180345760A1 (en) 2018-12-06
SI2738259T1 (sl) 2020-06-30
US20180362663A1 (en) 2018-12-20
US20210105984A1 (en) 2021-04-15
RS59661B1 (sr) 2020-01-31

Similar Documents

Publication Publication Date Title
IL273986B (en) adam6 mice
AP2014007621A0 (en) 2-Thiopyrimidinones
AU339404S (en) Pen
GB201100001D0 (en) TidySqueeze2
GB201109865D0 (en) Touchiness interaction
AP00723S1 (en) Autorickshaw
AP2011000390S (en) Kuppkraft